Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559354 | 1.00 | KDM4E (0.62) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL16181811 | 0.92 | KCNA3 (0.52) | KDM4EOPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL13559342 | 0.84 | KCNA3 (0.51) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL13559344 | 0.82 | POLB (0.46) | KDM4EALDH1A1OPRK1CYP2D6TSHR | |
| SCHEMBL469063 | 0.82 | KDM4E (0.65) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL468956 | 0.82 | KDM4E (0.65) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL16181767 | 0.81 | POLB (0.45) | KDM4EALDH1A1KMT2AMEN1CYP2D6 | |
| SCHEMBL435991 | 0.79 | KDM4E (0.61) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL438701 | 0.79 | KDM4E (0.61) | KDM4EALDH1A1KMT2AMEN1OPRK1 | |
| SCHEMBL13985382 | 0.78 | SIGMAR1 (0.50) | KDM4EALDH1A1KMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | KDM4E 2253/4885ALDH1A1 466/4885KMT2A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.